Zobrazeno 1 - 10 of 108 pro vyhledávání: '"G Pineton de Chambrun"'
1
Defining and Assessing the Reproducibility of Crohn’s Disease Endoscopic Lesions: A Delphi-like Method from the GETAID
Autor: Lucine Vuitton, Edouard Louis, G Pineton de Chambrun, Anne-Laure Pelletier, P. Marteau, A. Buisson, D. Laharie, P. Seksik, Gwenola Vernier-Massouille, Yoram Bouhnik, Aurelien Amiot, Jean-Yves Mary, Jérôme Filippi, Driffa Moussata, Laurent Peyrin-Biroulet, Guillaume Cadiot, Mathieu Allez, Jean-Louis Dupas, Stéphane Nancey, Alain Attar, Maria Nachury, Antoine Blain
Publikováno v: Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2021, 15 (6), pp.1000-1008. ⟨10.1093/ecco-jcc/jjaa250⟩
Background and Aims Defining and assessing the reproducibility of Crohn’s disease [CD] endoscopic lesions is essential in assessing endoscopic healing. Methods Twelve endoscopic CD experts from the GETAID defined aphthoid erosions [AE], superficial
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c669fa6b5227e0f11920159dcfca1041
https://doi.org/10.1093/ecco-jcc/jjaa250
Zobrazit plný text záznamu
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
P355 Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)
Autor: A Buisson, M Fumery, M Serrero, L Orsat, S Nancey, P Rivière, R Altwegg, L Peyrin-Biroulet, M Nachury, X Hébuterne, C Gilletta, M Flamant, S Viennot, G Bouguen, A Amiot, S Mathieu, L Vuitton, L Plastaras, A Bourreille, L Caillo, F Goutorbe, G Pineton de Chambrun, A Attar, X Roblin, B Pereira, B Pariente
Publikováno v: Journal of Crohn's and Colitis. 14:S337-S338
Background The multiplication of therapeutic options with close efficacy and safety, leads to consider acceptability of treatment regimen as a key point for therapeutic decision in inflammatory bowel disease (IBD). We aimed to compare acceptability o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e58af3bb0d20f622c020b11987f42049
https://doi.org/10.1093/ecco-jcc/jjz203.484
Zobrazit plný text záznamu
6
4CPS-143 Evaluation of knowledge of patients with inflammatory bowel disease treated by the reference product concerning biosimilars: role of clinical pharmacists
Autor: E Coget, D Rosant, Pierre Blanc, GP Pageaux, V Velasco Gonzalvo, G Pineton de Chambrun, D Huc, C Breuker, P Laffont-Lozes, Romain Altwegg
Publikováno v: Section 4: Clinical Pharmacy Services.
Background Anti-TNF monoclonal antibodies such as infliximab have revolutionised the treatment of patients with inflammatory bowel disease (IBD). For a few years several biosimilars of the reference product (RP) have reached the European market and s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e73d60de993f9dbc65acfa5a6b7649c
https://doi.org/10.1136/ejhpharm-2019-eahpconf.292
Zobrazit plný text záznamu
8
4CPS-144 Establishment of a pharmaceutical standardised interview concerning biosimilars of infliximab in the daycare clinic of a gastroenterology department for patients affected by inflammatory bowel disease
Autor: GP Pageaux, P Laffont-Lozes, Pierre Blanc, V Velasco Gonzalvo, G Pineton de Chambrun, Cyril Breuker, D Rosant, E Coget, D Huc, Romain Altwegg
Publikováno v: Section 4: Clinical Pharmacy Services.
Background Anti-TNF monoclonal antibodies such as infliximab effectively treat inflammatory bowel disease (IBD). Currently they are recommended after failure or contraindication of corticosteroid/immunosuppressive therapy. The use of infliximab’s b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f1e03bb7de51ce7f72aa9c6305666f66
https://doi.org/10.1136/ejhpharm-2019-eahpconf.293
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
P719 Effectiveness and safety of ustekinumab induction therapy in ulcerative colitis: A GETAID real-world cohort study
Autor: Aurelien Amiot, Jérôme Filippi, G Pineton de Chambrun, L Peyrin-Biroulet, Jean-Marc Gornet, Guillaume Cadiot, A Vered, Anne Bourrier, Yoram Bouhnik, Lucine Vuitton, P Benjamin, D. Laharie, Stephanie Viennot, Mathurin Fumery, Stéphane Nancey, Romain Altwegg, Guillaume Bouguen, Stéphane Nahon, Xavier Roblin, S Melanie, Cyrielle Gilletta
Publikováno v: Journal of Crohn's and Colitis. 14:S579-S579
Background Phase III trials have demonstrated the efficacy and safety of ustekinumab in moderate-to-severe ulcerative colitis (UC), but no real-life data is currently available. Methods Between January and September 2019, all consecutive patients wit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fa7f0465ffcd091ac625d9a4bab60980
https://doi.org/10.1093/ecco-jcc/jjz203.847
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje